# OGN — Organon & Co · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** OGN  
**Sources:** 23  
**Published:** 2026-10-28  
**Canonical:** https://app.k3vl4r.com/research/deep-research-ogn-organon-co-catalysts-narrative-risks-9814

---

## Organon & Co. (NYSE: OGN) — Research Snapshot as of 2026-10-28

### Context
Organon is a global pharmaceutical company spun off from Merck (known as MSD outside the U.S.), focused on women's health, biosimilars, and established/off-patent brands, headquartered in Jersey City, NJ [[2]](https://sunpharma.com/wp-content/uploads/2026/04/Press-Release-Sun-Pharma-signs-Definitive-Agreement-to-Acquire-Organon.pdf), [[21]](https://finance.yahoo.com/quote/OGN/), [[24]](https://en.wikipedia.org/wiki/Organon_%26_Co.). It trades at roughly $13.77 on October 28, 2026, with a market capitalization of ~$3.6B, and has been trading at the top of its 52-week range (~$5.69–$13.83) after roughly a +96% total return over the past 12 months [[6]](https://www.ad-hoc-news.de/boerse/news/corporate-news/organon-stock-presents-new-vtama-analysis-ahead-of-november-results/70227530), [[10]](https://tickernerd.com/stock/ogn-forecast/), [[19]](https://stockanalysis.com/stocks/ogn/forecast/), [[20]](https://stockanalysis.com/stocks/ogn/).

---

### 1. Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-ogn-organon-co-catalysts-narrative-risks-9814 (free to sign up)._